Home - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases Read …
News & Events - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Who We Are - Organovo, Inc.
Organovo is a biotechnology company that develops new medicines based on its 3D human tissue models of inflammatory bowel disease and other conditions. It has a lead candidate, FXR314, in Phase 2 clinical trials for ulcerative colitis and plans to …
Organovo Highlights FXR314 Combination Therapy Potential and …
Nov 8, 2023 · In both Organovo’s proprietary 3D human models and in preclinical animal models of disease, FXR314 treatment demonstrates a reduction in the disruption of the intestinal lining, which protects against bacteria penetrating into the intestinal wall.
Pipeline - Organovo, Inc.
Organovo is a biotechnology company that uses 3D human tissue models to create new medicines for inflammatory bowel diseases, liver fibrosis and other indications. Learn about its lead candidate FXR314 and its novel drug in development for Crohn's disease and other targets.
Organovo On Track to Establish Human 3D Disease Model in …
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.
About - Organovo, Inc.
© 2024 Organovo Holdings Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121
Organovo Achieves 3D Tissue Model for Crohn’s Disease
May 17, 2022 · Organovo believes that its 3D tissue technologies are well suited to drug and target discovery in IBD because they contain a functional intestinal epithelium that is affected by disease and a stromal layer demonstrating disease-dependent fibrosis, key targets for therapy.
3D bioprinted therapeutic liver tissue - Organovo, Inc.
Organovo presents its NovoGen Bioprinter® Platform for creating implantable human liver patches for liver diseases and injury. Learn about the design, functionality, and engraftment of the 3D bioprinted liver tissue in small animal models.
Media Coverage - Organovo, Inc.
Merck 'bio-inks' deal to use Organovo's 3D printed liver for preclinical studies